Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Group A streptococcus: Virulence factors and pathogenic mechanisms

Dennis L Stevens, MD, PhD
Amy Bryant, PhD
Section Editor
Daniel J Sexton, MD
Deputy Editor
Elinor L Baron, MD, DTMH


Group A Streptococcus (GAS), also known as Streptococcus pyogenes, cause a broad range of infections and complications. The interaction between the host and this important pathogen will be reviewed here. The wide variety of GAS infections are discussed separately. (See related topics.)


S. pyogenes is a facultative, gram-positive coccus that grows in chains. It causes an array of infections involving the respiratory tract and soft tissues ranging in severity from mild to severe. The only known reservoirs are the skin and mucous membranes of the human host. The pathogenic mechanisms underlying these infections are poorly understood, largely because each is the culmination of highly complex interactions between the human host defense mechanisms and specific virulence factors of the organism.


Group A Streptococcus (GAS) requires complex media containing blood products. It grows best in an environment of 10 percent carbon dioxide and produces pinpoint colonies on blood agar plates; these are surrounded by a zone of complete (beta) hemolysis.

Classification schemes — The Lancefield classification divides streptococci into types A through O based upon acid-extractable carbohydrate antigens of cell-wall material [1]. GAS has also been subdivided based upon the surface expression of M and T antigens. Subtyping strains of GAS has proven invaluable for epidemiologic studies. High-resolution genotyping provides more specific determination of relatedness among strains isolated in outbreaks of GAS infections [2]. Finally, rapid sequencing of the gene-encoding M protein provides a rapid, definitive comparison of M-typeable and M-nontypeable strains. (See 'M proteins' below.)


A number of different constituents and products of group A Streptococcus (GAS) have been identified as virulence factors (figure 1).

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Jul 21, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. LANCEFIELD RC. Current knowledge of type-specific M antigens of group A streptococci. J Immunol 1962; 89:307.
  2. Stanley J, Desai M, Xerry J, et al. High-resolution genotyping elucidates the epidemiology of group A streptococcus outbreaks. J Infect Dis 1996; 174:500.
  3. Fischetti VA. Streptococcal M protein. Sci Am 1991; 264:58.
  4. Fischetti VA, Horstmann RD, Pancholi V. Location of the complement factor H binding site on streptococcal M6 protein. Infect Immun 1995; 63:149.
  5. Peterson PK, Schmeling D, Cleary PP, et al. Inhibition of alternative complement pathway opsonization by group A streptococcal M protein. J Infect Dis 1979; 139:575.
  6. Dale JB, Chiang EC. Intranasal immunization with recombinant group A streptococcal M protein fragment fused to the B subunit of Escherichia coli labile toxin protects mice against systemic challenge infections. J Infect Dis 1995; 171:1038.
  7. Tran PO, Johnson DR, Kaplan EL. The presence of M protein in nontypeable group A streptococcal upper respiratory tract isolates from Southeast Asia. J Infect Dis 1994; 169:658.
  8. Single LA, Martin DR. Clonal differences within M-types of the group A Streptococcus revealed by pulsed field gel electrophoresis. FEMS Microbiol Lett 1992; 70:85.
  9. de Malmanche SA, Martin DR. Protective immunity to the group A Streptococcus may be only strain specific. Med Microbiol Immunol 1994; 183:299.
  10. Beall B, Facklam R, Thompson T. Sequencing emm-specific PCR products for routine and accurate typing of group A streptococci. J Clin Microbiol 1996; 34:953.
  11. O'Loughlin RE, Roberson A, Cieslak PR, et al. The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000-2004. Clin Infect Dis 2007; 45:853.
  12. McNeil SA, Halperin SA, Langley JM, et al. Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers. Clin Infect Dis 2005; 41:1114.
  13. Hu MC, Walls MA, Stroop SD, et al. Immunogenicity of a 26-valent group A streptococcal vaccine. Infect Immun 2002; 70:2171.
  14. Cohen-Poradosu R, Kasper DL. Group A streptococcus epidemiology and vaccine implications. Clin Infect Dis 2007; 45:863.
  15. Obaro SK, Adegbola RA, Banya WA, Greenwood BM. Carriage of pneumococci after pneumococcal vaccination. Lancet 1996; 348:271.
  16. Jaggi P, Dale JB, Chiang E, et al. Age-associated differences in prevalence of group A streptococcal type-specific M antibodies in children. Eur J Pediatr 2009; 168:679.
  17. Tweten RK. Nucleotide sequence of the gene for perfringolysin O (theta-toxin) from Clostridium perfringens: significant homology with the genes for streptolysin O and pneumolysin. Infect Immun 1988; 56:3235.
  18. Alouf JE, Geoffroy C. Structure activity relationships in sulfhydryl-activated toxins. In: Bacterial protein toxins, Freer JH, Jeljaszewicz J (Eds), Academic Press, London 1984. p.165.
  19. RANTZ LA, RANDALL E, RANTZ HH. Antistreptolysin O; a study of this antibody in health and in hemolytic streptococcus respiratory disease in man. Am J Med 1948; 5:3.
  20. Lottenberg R, Broder CC, Boyle MD. Identification of a specific receptor for plasmin on a group A streptococcus. Infect Immun 1987; 55:1914.
  21. Lütticken R, Lütticken D, Johnson DR, Wannamaker LW. Application of a new method for detecting streptococcal nicotinamide adenine dinucleotide glycohydrolase to various M types of Streptoccus pyogenes. J Clin Microbiol 1976; 3:533.
  22. Stevens DL, Salmi DB, McIndoo ER, Bryant AE. Molecular epidemiology of nga and NAD glycohydrolase/ADP-ribosyltransferase activity among Streptococcus pyogenes causing streptococcal toxic shock syndrome. J Infect Dis 2000; 182:1117.
  23. Zhu L, Olsen RJ, Nasser W, et al. A molecular trigger for intercontinental epidemics of group A Streptococcus. J Clin Invest 2015; 125:3545.
  24. Barsumian EL, Schlievert PM, Watson DW. Nonspecific and specific immunological mitogenicity by group A streptococcal pyrogenic exotoxins. Infect Immun 1978; 22:681.
  25. Nida SK, Ferretti JJ. Phage influence on the synthesis of extracellular toxins in group A streptococci. Infect Immun 1982; 36:745.
  26. Kline JB, Collins CM. Analysis of the superantigenic activity of mutant and allelic forms of streptococcal pyrogenic exotoxin A. Infect Immun 1996; 64:861.
  27. Hauser AR, Stevens DL, Kaplan EL, Schlievert PM. Molecular analysis of pyrogenic exotoxins from Streptococcus pyogenes isolates associated with toxic shock-like syndrome. J Clin Microbiol 1991; 29:1562.
  28. Stevens DL, Tanner MH, Winship J, et al. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med 1989; 321:1.
  29. Köhler W, Gerlach D, Knöll H. Streptococcal outbreaks and erythrogenic toxin type A. Zentralbl Bakteriol Mikrobiol Hyg A 1987; 266:104.
  30. Hallas G. The production of pyrogenic exotoxins by group A streptococci. J Hyg (Lond) 1985; 95:47.
  31. Chaussee MS, Liu J, Stevens DL, Ferretti JJ. Genetic and phenotypic diversity among isolates of Streptococcus pyogenes from invasive infections. J Infect Dis 1996; 173:901.
  32. Iwasaki M, Igarashi H, Hinuma Y, Yutsudo T. Cloning, characterization and overexpression of a Streptococcus pyogenes gene encoding a new type of mitogenic factor. FEBS Lett 1993; 331:187.
  33. Norrby-Teglund A, Newton D, Kotb M, et al. Superantigenic properties of the group A streptococcal exotoxin SpeF (MF). Infect Immun 1994; 62:5227.
  34. Mollick JA, Miller GG, Musser JM, et al. A novel superantigen isolated from pathogenic strains of Streptococcus pyogenes with aminoterminal homology to staphylococcal enterotoxins B and C. J Clin Invest 1993; 92:710.
  35. Sriskandan S, Unnikrishnan M, Krausz T, Cohen J. Mitogenic factor (MF) is the major DNase of serotype M89 Streptococcus pyogenes. Microbiology 2000; 146 ( Pt 11):2785.
  36. Stevens DL. Streptococcus pyogenes Infections. In: Internal Medicine, 4th ed, Stein JH (Ed), Mosby, St. Louis 1994. p.2078.
  37. Wessels MR, Moses AE, Goldberg JB, DiCesare TJ. Hyaluronic acid capsule is a virulence factor for mucoid group A streptococci. Proc Natl Acad Sci U S A 1991; 88:8317.
  38. Schrager HM, Albertí S, Cywes C, et al. Hyaluronic acid capsule modulates M protein-mediated adherence and acts as a ligand for attachment of group A Streptococcus to CD44 on human keratinocytes. J Clin Invest 1998; 101:1708.
  39. Cywes C, Wessels MR. Group A Streptococcus tissue invasion by CD44-mediated cell signalling. Nature 2001; 414:648.
  40. Gryllos I, Cywes C, Shearer MH, et al. Regulation of capsule gene expression by group A Streptococcus during pharyngeal colonization and invasive infection. Mol Microbiol 2001; 42:61.
  41. Hasty DL, Ofek I, Courtney HS, Doyle RJ. Multiple adhesins of streptococci. Infect Immun 1992; 60:2147.
  42. Greenblatt J, Boackle RJ, Schwab JH. Activation of the alternate complement pathway by peptidoglycan from streptococcal cell wall. Infect Immun 1978; 19:296.
  43. Bisno AL. Alternate complement pathway activation by group A streptococci: role of M-protein. Infect Immun 1979; 26:1172.
  44. Edwards RJ, Taylor GW, Ferguson M, et al. Specific C-terminal cleavage and inactivation of interleukin-8 by invasive disease isolates of Streptococcus pyogenes. J Infect Dis 2005; 192:783.
  45. Hidalgo-Grass C, Dan-Goor M, Maly A, et al. Effect of a bacterial pheromone peptide on host chemokine degradation in group A streptococcal necrotising soft-tissue infections. Lancet 2004; 363:696.
  46. Thern A, Stenberg L, Dahlbäck B, Lindahl G. Ig-binding surface proteins of Streptococcus pyogenes also bind human C4b-binding protein (C4BP), a regulatory component of the complement system. J Immunol 1995; 154:375.
  47. Hanski E, Caparon M. Protein F, a fibronectin-binding protein, is an adhesin of the group A streptococcus Streptococcus pyogenes. Proc Natl Acad Sci U S A 1992; 89:6172.
  48. Natanson S, Sela S, Moses AE, et al. Distribution of fibronectin-binding proteins among group A streptococci of different M types. J Infect Dis 1995; 171:871.
  49. Akesson P, Sjöholm AG, Björck L. Protein SIC, a novel extracellular protein of Streptococcus pyogenes interfering with complement function. J Biol Chem 1996; 271:1081.
  50. Egesten A, Eliasson M, Johansson HM, et al. The CXC chemokine MIG/CXCL9 is important in innate immunity against Streptococcus pyogenes. J Infect Dis 2007; 195:684.
  51. Katerov V, Lindgren PE, Totolian AA, Schalén C. Streptococcal opacity factor: a family of bifunctional proteins with lipoproteinase and fibronectin-binding activities. Curr Microbiol 2000; 40:149.
  52. Bessen DE, Sotir CM, Readdy TL, Hollingshead SK. Genetic correlates of throat and skin isolates of group A streptococci. J Infect Dis 1996; 173:896.
  53. Bryant AE, Bayer CR, Huntington JD, Stevens DL. Group A streptococcal myonecrosis: increased vimentin expression after skeletal-muscle injury mediates the binding of Streptococcus pyogenes. J Infect Dis 2006; 193:1685.
  54. Raeder R, Woischnik M, Podbielski A, Boyle MD. A secreted streptococcal cysteine protease can cleave a surface-expressed M1 protein and alter the immunoglobulin binding properties. Res Microbiol 1998; 149:539.
  55. Johnson DR, Stevens DL, Kaplan EL. Epidemiologic analysis of group A streptococcal serotypes associated with severe systemic infections, rheumatic fever, or uncomplicated pharyngitis. J Infect Dis 1992; 166:374.
  56. Stevens DL. Invasive group A streptococcus infections. Clin Infect Dis 1992; 14:2.
  57. Fast DJ, Schlievert PM, Nelson RD. Toxic shock syndrome-associated staphylococcal and streptococcal pyrogenic toxins are potent inducers of tumor necrosis factor production. Infect Immun 1989; 57:291.
  58. Hackett SP, Schlievert PM, Stevens DL. Cytokine production by human mononuclear cells in response to streptococcal exotoxins. Clin Res 1991; 39:189A.
  59. Norrby-Teglund A, Norgren M, Holm SE, et al. Similar cytokine induction profiles of a novel streptococcal exotoxin, MF, and pyrogenic exotoxins A and B. Infect Immun 1994; 62:3731.
  60. Müller-Alouf H, Alouf JE, Gerlach D, et al. Cytokine production by murine cells activated by erythrogenic toxin type A superantigen of Streptococcus pyogenes. Immunobiology 1992; 186:435.
  61. Mollick JA, Rich RR. Characterization of a superantigen from a pathogenic strain of Streptococcus pyogenes. Clin Res 1991; 39:213A.
  62. Hackett SP, Stevens DL. Streptococcal toxic shock syndrome: synthesis of tumor necrosis factor and interleukin-1 by monocytes stimulated with pyrogenic exotoxin A and streptolysin O. J Infect Dis 1992; 165:879.
  63. Kotb M, Ohnishi H, Majumdar G, et al. Temporal relationship of cytokine release by peripheral blood mononuclear cells stimulated by the streptococcal superantigen pep M5. Infect Immun 1993; 61:1194.
  64. Watanabe-Ohnishi R, Low DE, McGeer A, et al. Selective depletion of V beta-bearing T cells in patients with severe invasive group A streptococcal infections and streptococcal toxic shock syndrome. Ontario Streptococcal Study Project. J Infect Dis 1995; 171:74.
  65. Kotb M, Norrby-Teglund A, McGeer A, et al. An immunogenetic and molecular basis for differences in outcomes of invasive group A streptococcal infections. Nat Med 2002; 8:1398.
  66. Stevens DL, Bryant AE, Hackett SP. Gram positive shock. Curr Opin Infect Dis 1992; 5:355.
  67. Müller-Alouf H, Alouf JE, Gerlach D, et al. Comparative study of cytokine release by human peripheral blood mononuclear cells stimulated with Streptococcus pyogenes superantigenic erythrogenic toxins, heat-killed streptococci, and lipopolysaccharide. Infect Immun 1994; 62:4915.
  68. Hackett SP, Stevens DL. Superantigens associated with staphylococcal and streptococcal toxic shock syndrome are potent inducers of tumor necrosis factor-beta synthesis. J Infect Dis 1993; 168:232.
  69. Kapur V, Majesky MW, Li LL, et al. Cleavage of interleukin 1 beta (IL-1 beta) precursor to produce active IL-1 beta by a conserved extracellular cysteine protease from Streptococcus pyogenes. Proc Natl Acad Sci U S A 1993; 90:7676.
  70. Burns EH Jr, Marciel AM, Musser JM. Activation of a 66-kilodalton human endothelial cell matrix metalloprotease by Streptococcus pyogenes extracellular cysteine protease. Infect Immun 1996; 64:4744.
  71. Guilherme L, Cunha-Neto E, Coelho V, et al. Human heart-infiltrating T-cell clones from rheumatic heart disease patients recognize both streptococcal and cardiac proteins. Circulation 1995; 92:415.
  72. Quinn A, Ward K, Fischetti VA, et al. Immunological relationship between the class I epitope of streptococcal M protein and myosin. Infect Immun 1998; 66:4418.
  73. Gulizia JM, Cunningham MW, McManus BM. Immunoreactivity of anti-streptococcal monoclonal antibodies to human heart valves. Evidence for multiple cross-reactive epitopes. Am J Pathol 1991; 138:285.
  74. Batsford SR, Mezzano S, Mihatsch M, et al. Is the nephritogenic antigen in post-streptococcal glomerulonephritis pyrogenic exotoxin B (SPE B) or GAPDH? Kidney Int 2005; 68:1120.
  75. Cu GA, Mezzano S, Bannan JD, Zabriskie JB. Immunohistochemical and serological evidence for the role of streptococcal proteinase in acute post-streptococcal glomerulonephritis. Kidney Int 1998; 54:819.
  76. Luo YH, Kuo CF, Huang KJ, et al. Streptococcal pyrogenic exotoxin B antibodies in a mouse model of glomerulonephritis. Kidney Int 2007; 72:716.
  77. Nordstrand A, Norgren M, Ferretti JJ, Holm SE. Streptokinase as a mediator of acute post-streptococcal glomerulonephritis in an experimental mouse model. Infect Immun 1998; 66:315.